» Articles » PMID: 21123948

Thioredoxin-like 2 Regulates Human Cancer Cell Growth and Metastasis Via Redox Homeostasis and NF-κB Signaling

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2010 Dec 3
PMID 21123948
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells have an efficient antioxidant system to counteract their increased generation of ROS. However, whether this ability to survive high levels of ROS has an important role in the growth and metastasis of tumors is not well understood. Here, we demonstrate that the redox protein thioredoxin-like 2 (TXNL2) regulates the growth and metastasis of human breast cancer cells through a redox signaling mechanism. TXNL2 was found to be overexpressed in human cancers, including breast cancers. Knockdown of TXNL2 in human breast cancer cell lines increased ROS levels and reduced NF-κB activity, resulting in inhibition of in vitro proliferation, survival, and invasion. In addition, TXNL2 knockdown inhibited tumorigenesis and metastasis of these cells upon transplantation into immunodeficient mice. Furthermore, analysis of primary breast cancer samples demonstrated that enhanced TXNL2 expression correlated with metastasis to the lung and brain and with decreased overall patient survival. Our studies provided insight into redox-based mechanisms underlying tumor growth and metastasis and suggest that TXNL2 could be a target for treatment of breast cancer.

Citing Articles

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers.

Hu Q, Chen J, Yang W, Xu M, Zhou J, Tan J Front Oncol. 2023; 13:990551.

PMID: 36845676 PMC: 9947857. DOI: 10.3389/fonc.2023.990551.


Effects of Antioxidant Gene Overexpression on Stress Resistance and Malignization In Vitro and In Vivo: A Review.

Tavleeva M, Belykh E, Rybak A, Rasova E, Chernykh A, Ismailov Z Antioxidants (Basel). 2022; 11(12).

PMID: 36552527 PMC: 9774954. DOI: 10.3390/antiox11122316.


Glutathione and Its Metabolic Enzymes in Gliomal Tumor Tissue and the Peritumoral Zone at Different Degrees of Anaplasia.

Obukhova L, Kopytova T, Murach E, Shchelchkova N, Kontorshchikova C, Medyanik I Curr Issues Mol Biol. 2022; 44(12):6439-6449.

PMID: 36547100 PMC: 9777065. DOI: 10.3390/cimb44120439.


ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment.

Xu Y, He X, Deng J, Xiong L, Chen B, Chen J Oxid Med Cell Longev. 2022; 2022:4713518.

PMID: 35585886 PMC: 9110211. DOI: 10.1155/2022/4713518.


Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway.

Zhang S, Kong D, Ma G, Liu C, Yang Y, Liu S Acta Pharmacol Sin. 2022; 43(9):2212-2225.

PMID: 35217812 PMC: 9433393. DOI: 10.1038/s41401-021-00844-9.


References
1.
Witte S, Villalba M, Bi K, Liu Y, Isakov N, Altman A . Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem. 2000; 275(3):1902-9. DOI: 10.1074/jbc.275.3.1902. View

2.
Jones D . Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008; 295(4):C849-68. PMC: 2575825. DOI: 10.1152/ajpcell.00283.2008. View

3.
Luo J, Kamata H, Karin M . IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005; 115(10):2625-32. PMC: 1236696. DOI: 10.1172/JCI26322. View

4.
Pyeon D, Newton M, Lambert P, den Boon J, Sengupta S, Marsit C . Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007; 67(10):4605-19. PMC: 2858285. DOI: 10.1158/0008-5472.CAN-06-3619. View

5.
Hong K, Kim J, Hong J, Yoon H, Lee J, Hong S . Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res. 2009; 28:28. PMC: 2651854. DOI: 10.1186/1756-9966-28-28. View